OXFD Stock News 19.63 05/13/2014 17:24:13 Oxford Immunotec Global

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oxford Immunotec Global Plc (OXFD) 19.63 $OXFD

Oxford Immunotec Reports First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 6:06AM CDT
-- 2014 First Quarter Revenue of $12.3 Million Increased 60% Compared to Prior Year

Oxford Immunotec Schedules First Quarter 2014 Earnings Release and Conference Call for May 6, 2014
GlobeNewswire - Thu Apr 24, 12:04PM CDT
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it plans to release first quarter 2014 financial results prior to market open on Tuesday, May 6, 2014. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.

Oxford Immunotec receives 2014 Queen's Award for Enterprise
GlobeNewswire - Mon Apr 21, 4:00AM CDT
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it has received a Queen's Award for Enterprise - the UK's highest accolade in business success.

Oxford Immunotec Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Tue Mar 04, 6:11AM CST
-- Fourth Quarter Revenues of $10.2 Million Increased 94% Compared to Prior Year Period

Oxford Immunotec : Schedules Fourth Quarter and Full Year 2013 Earnings Release and Conference Call for March 4, 2014
Thomson Reuters ONE - Mon Feb 24, 1:05PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) today announced that it plans to release fourth quarter and full year 2013 financial results prior to market open on Tuesday, March 4, 2014. Dr. Peter Wrighton-Smith, Chief Executive Officer and Rick Altieri, Chief Financial Officer will host a conference call to review the Company's results at 8:00am Eastern Time the same day. The call will be concurrently webcast.

Dr. Peter Wrighton-Smith Named UK BioIndustry Association (BIA) Entrepreneur of the Year
GlobeNewswire - Fri Jan 31, 5:00AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD) announced today that its CEO, Dr. Peter Wrighton-Smith has been named the UK BioIndustry Association Entrepreneur of the Year.

Oxford Immunotec Announces Preliminary Fourth Quarter and Fiscal 2013 Revenue and Initiates 2014 Fiscal Year Guidance
GlobeNewswire - Mon Jan 13, 5:00AM CST
-- Preliminary fourth quarter revenue of between $10.1 and $10.5 million, an increase of 91% to 99% over the prior year

Oxford Immunotec to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 12:08PM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that Peter Wrighton-Smith Ph.D., Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the 32 Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California on Thursday, January 16, 2014 at 12:30 pm PT.

Upcoming Presentations, Milestone Payments, Quarterly Financial Results, and New Appointments - Research Report on Medivation, Acceleron, Aerie, Arrowhead, and Oxford Immunotec
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), Acceleron Pharma, Inc. (NASDAQ: XLRN), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Arrowhead Research Corp. (NASDAQ: ARWR), and Oxford Immunotec Global PLC (NASDAQ: OXFD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Why Mattress Firm, Navios Maritime Holdings, and Oxford Immunotec Global Soared Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Dec 05, 7:01PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. For the stock market, a fifth straight day of losses for the...

Oxford Immunotec Global PLC Announces Appointment of Herm Rosenman to the Board of Directors
Business Wire - Mon Dec 02, 11:47AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) (the "Company" announced today that Herman ("Herm" Rosenman has been appointed as a member of the Company's Board of Directors and will serve as Chairman of the Board's Audit Committee. Mr. Rosenman served most recently as Senior Vice President, Finance and Chief Financial Officer of Gen-Probe Incorporated, a publicly traded molecular diagnostics company, which was acquired by Hologic, Inc. in 2012. He is currently a member of the Board of Directors and Audit Committee Chairman of Vivus, Inc., a publicly traded biopharmaceutical company, Medistem, Inc., a stem cell therapy company, and BioFire Diagnostics, Inc., a molecular diagnostics company. "Herm brings significant experience to our Board of Directors based upon his past positions as both a senior executive and a director of companies in the diagnostics and healthcare sectors," commented Peter Wrighton-Smith, Ph.D., the Company's Chief Executive Officer. "We are delighted to have Herm join the Board and look forward to working with him to build the Company."

Oxford Immunotec Global PLC Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option
Business Wire - Mon Dec 02, 11:46AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) today announced the closing of its initial public offering of 6,164,000 ordinary shares at an initial public offering price of $12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 804,000 additional ordinary shares. Oxford estimates net proceeds from the offering to be approximately $62.8 million after deducting underwriting discounts and commissions and estimated offering expenses. The ordinary shares are listed on The NASDAQ Global Market under the trading symbol "OXFD."

Oxford Immunotec Global PLC Announces Pricing of Initial Public Offering
Business Wire - Fri Nov 22, 7:47AM CST
Oxford Immunotec Global PLC (NASDAQ: OXFD) (the "Company" announced today that its initial public offering of 5,360,000 ordinary shares priced at $12.00 per share. The Company has granted the underwriters the option to purchase up to an additional 804,000 ordinary shares at the initial public offering price less the underwriting discount. The ordinary shares are expected to begin trading on The NASDAQ Global Market on November 22, 2013 under the trading symbol "OXFD."
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 114

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 7

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 66

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 26

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US: A Decade of Impressive Stock Growth Revealed

Updated Category News Views 142

T-Mobile US and Its Remarkable Growth Journey T-Mobile US (NASDAQ: TMUS) has shown exceptional growth over the last decade. With an annualized return rate of 20.05%, the company has outpaced the broader market by 8.22%. As of the latest information available, T-Mobile's market capitalization stands at an impressive $269.40 billion, highlighting its substantial position...

Continue Reading
Analysts Adjust TFI International's Forecasts After Q3 Report

Updated Category News Views 67

TFI International Reports Weaker-Than-Expected Q3 Earnings After the market closed on a recent Monday, TFI International (NYSE: TFII) announced its quarterly earnings figures, which unfortunately fell below expectations. The company reported earnings of $1.60 per share, compared to analyst predictions of $1.78 per share. In addition, TFI International's quarterly revenue...

Continue Reading
C3.ai Investors Face Class Action Amidst Poor Financial Results

Updated Category News Views 179

C3.ai Class Action Overview The Portnoy Law Firm is stepping forward to represent investors of C3.ai, Inc. as a class action develops. This legal move comes after concerning preliminary financial results announced by the company. Investors who purchased securities of C3 during the specified class period are encouraged to engage with the firm. Details of the Legal Class...

Continue Reading
21st.BIO Seeks EU Nod for Precision Fermentation Tech

Updated Category News Views 172

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Continue Reading
Key Pfizer Executives Support Current Leadership Amid Challenges

Updated Category News Views 105

Support for Pfizer's Leadership from Former Executives In a recent statement, former Pfizer executives, Ian Read and Frank D'Amelio, clarified their stance regarding the ongoing campaign by activist investor Starboard Value. They emphasized that they will not be engaging with Starboard, which has been advocating for changes within the pharmaceutical giant to enhance its...

Continue Reading